相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia*
Cagla Kayabasi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Oliver Herrmann et al.
BMC CANCER (2019)
PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Xue Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells
Sylwia Flis et al.
CANCERS (2019)
Chronic Myeloid Leukemia: Beyond BCR-ABL1
Ting Zhou et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia
Cagla Kayabasi et al.
GENE (2017)
RAIN: RNA-protein Association and Interaction Networks
Alexander Junge et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2017)
Long Noncoding RNA and Cancer: A New Paradigm
Arunoday Bhan et al.
CANCER RESEARCH (2017)
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
Helena Agerstam et al.
BLOOD (2016)
Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia
Wen Tian Sun et al.
EXPERIMENTAL HEMATOLOGY (2016)
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
E. Nievergall et al.
LEUKEMIA (2016)
Long non-coding RNAs in normal and malignant hematopoiesis
Lucia Nobili et al.
ONCOTARGET (2016)
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
Seiichi Okabe et al.
ONCOTARGET (2016)
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation
Paolo Gallipoli et al.
BLOOD (2013)
Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
J. Kuroda et al.
CURRENT CANCER DRUG TARGETS (2013)
Long Non-Coding RNAs in Haematological Malignancies
Andoni Garitano-Trojaola et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Bin Zhang et al.
CANCER CELL (2012)
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Thomas O'Hare et al.
CLINICAL CANCER RESEARCH (2011)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
Juan Carlos Montero et al.
CLINICAL CANCER RESEARCH (2011)
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Ravin J. Garg et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors
K. Nunoda et al.
ONCOGENE (2007)
RNA maps reveal new RNA classes and a possible function for pervasive transcription
Philipp Kapranov et al.
SCIENCE (2007)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia
J. Kuroda et al.
CELL DEATH AND DIFFERENTIATION (2007)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (vol 103, pg 14907, 2006)
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia
DJ Barnes et al.
ONCOGENE (2005)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
